IL1B and lung carcinoma: In an analysis of the CANTOS trial, incident new lung cancer diagnosis, lung, and total cancer mortality were significantly lower in the canakinumab-treated population compared to placebo, suggesting that the anti-inflammatory effect of blocking IL-1β innate immunity may protect from the development of lung cancer [99].